The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has ...
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...
Zacks Investment Research on MSN
FDA grants priority review to Roche's early-stage breast cancer NDA
Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for its investigational candidate, ...
Discover expert insights on head and neck cancer trial updates, including the efficacy of amivantamab and pembrolizumab ...
New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.
ASCO 2026 features promising research on hepatobiliary cancers, like new approaches to drugging the Wnt/beta-catenin pathway ...
Roche (RHHBF) stock is in focus as the FDA grants priority review for breast cancer therapy giredestrant with a target action ...
Objective To synthesise the evidence on the effects of exercise interventions in children and adolescents during and beyond cancer treatment, and to evaluate the methodological quality and certainty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results